Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ISAL 2023 | Challenges with immunotherapy in AML: on-target, off-tumor toxicity

In this video, Marina Konopleva, MD, PhD, Albert Einstein College of Medicine, New York City, NY, discusses challenges with developing immunotherapy in acute myeloid leukemia (AML), emphasizing the issue of shared antigens between AML cells and normal cells, which may lead to on-target, off-tumor toxicity. Prof. Konopleva also explains strategies which may be explored to overcome this challenge, including the use of antibody-drug conjugates (ADCs) and natural killer (NK) cells. This interview took place at the 18th International Symposium on Acute Leukemias (ISAL XVIII), held in Munich, Germany.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Disclosures

Consulting: AbbVie, Forty Seven, Daiichi, Precision Biosciences, Gilead, Genentech, Janssen, Sanofi, AstraZeneca, MEI Pharma, Menarini-Stemline Therapeutics,
Research Funding: AbbVie, Allogene, Cellectis, Forty Seven, Daiichi, Precision Biosciences, Gilead, Genentech, Sanofi, AstraZeneca, MEI Pharma, Menarini-Stemline Therapeutics, Rafael Pharmaceutical
Advisory board: AbbVie, Genentech, Janssen, Menarini-Stemline Therapeutics
Clinical trials support: AbbVie, Cellectis, Forty Seven, Genentech, AstraZeneca, Menarini-Stemline Therapeutics
Stockholder: Reata Pharmaceutical
Royalty: Reata Pharmaceutical